Deck Bio

Cambridge, United States

Deck Bio develops multi-target T cell engager immunotherapies for solid tumors.

$3.1M raised

Apr 2026

Seed

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Deck Bio raised?

Deck Bio has raised $3.1M in total funding. The most recent round was Seed. The last funding was announced in April 2026.

Who are Deck Bio's investors?

Deck Bio's investors include Mission BioCapital, BrightEdge - American Cancer Society, ScaleHealth, Impact Venture Partners.

Where is Deck Bio headquartered?

Deck Bio is headquartered in Cambridge, United States.

What does Deck Bio do?

Deck Bio develops multi-target T cell engager immunotherapies for solid tumors.

What stage is Deck Bio at?

Deck Bio is at the Seed stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated April 9, 2026.

MLA

"Deck Bio — Funding & Investors." VCBacked, April 9, 2026, https://www.vcbacked.co/company/deck-bio. Accessed July 3, 2026.

APA

VCBacked. (2026). Deck Bio — Funding & Investors. Retrieved July 3, 2026, from https://www.vcbacked.co/company/deck-bio

Wikipedia (cite web)

{{cite web |title=Deck Bio — Funding & Investors |url=https://www.vcbacked.co/company/deck-bio |website=VCBacked |access-date=July 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated April 9, 2026.